Federal Circuit Lets Apotex Challenge Acular Patent Again
The U.S. Court of Appeals for the Federal Circuit has granted Canadian generics maker Apotex Inc. a second chance to seek the invalidation of a patent for Allergan Inc.'s eye-inflammation treatment...To view the full article, register now.
Already a subscriber? Click here to view full article